The effect of telmisartan treatment on brown adipose tissue (BAT) in overweight hypertensive humans

Garvan Institute of Medical Research0 个研究点目标入组 48 人开始时间: 2014年6月6日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1. BMI: 20-30 kg/m2
•2. Disease status: uncomplicated hypertension on mono-therapy (ACE inhibitor or calcium channel blockers (CCB)) with stable blood pressure control for > 6 months.
•3. Willingness to give written informed consent and willingness to participate to and comply with the study

•* BMI <20 or >30 Kg/m2.
•* Age <18 or >45 years old.
•* Pregnant or breast-feeding.
•* History/laboratory (screening test) evidence of significant cardiovascular, endocrine, neoplastic, renal, hepatic or metabolic disorders, including hyperkalaeamia.
•* On more than 1 anti-hypertensive medication.
•* Known hypersensitivity to any angiotensin receptor blocker.
•* Current diabetes medication therapy (however, patients with pre-diabetes or diet-controlled diabetes not on medication may participate)
•* On therapies with possible effects on brown fat and or glycemia (e.g. beta-agonists (including inhaled formulations), beta-blockers, alpha-blockers, diuretics, glucocorticoids and/or hormone replacement).
•* Unwillingness to undergo blood pressure monitoring during treatment phase.
•* Claustrophobia.
•* History of illicit drug or alcohol abuse within the last 5 years; current use of drugs (by history) or alcohol (CAGE score>3).
•* Inability to provide written informed consent
•* Current use of medications/dietary supplements/alternative therapies known to alter endocrine/metabolic function.
•* Current use of antiplatelet or anticoagulants (if subjects decide to participate in optional tissue biopsies).
•* Current smoker or user of tobacco products
•* Current participation in weight loss programs (dietary, exercise or pharmacological) or more than 3 kg weight changes in last 6 months

发起方